特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
409618

多発血管性肉芽腫症 (ウェゲナー多発血管炎) :パイプライン製品の分析

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 119 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
多発血管性肉芽腫症 (ウェゲナー多発血管炎) :パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 119 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多発血管性肉芽腫症 (ウェゲナー多発血管炎)とは、血管の炎症を引き起こす難病の一種で、血管の炎症により様々な人体組織への血流が妨げられるという特徴があります。主な症状・徴候として、持続的な鼻水や鼻血、耳感染症、咳、胸痛、皮膚の爛れ、発熱などが挙げられます。また、年齢などが主な疾病素質に含まれています。主な治療法として、免疫抑制治療やコルチコステロイド剤などがあります。

当レポートでは、多発血管性肉芽腫症 (ウェゲナー多発血管炎)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

多発血管性肉芽腫症 (ウェゲナー多発血管炎) 概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Bionovis SA
  • Bristol-Myers Squibb Company
  • ChemoCentryx Inc
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • Iltoo Pharma
  • Panacea Biotec Ltd
  • Sandoz International GmbH
  • The International Biotechnology Center (IBC) Generium

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Biogen Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by ChemoCentryx Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Humanigen Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Iltoo Pharma, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Kyowa Kirin Co Ltd, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Mabion SA, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nanolek LLC, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxis, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12436IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H2 2020, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 2, 2, 3, 2 and 4 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Development
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Assessment
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in Therapeutics Development
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.